Context Therapeutics Inc (CNTX)
$2.04
Live
Performance
- $2.03$2.08$2.04
0.49%
Downside
Day's Volatility :2.4%
Upside
1.92%
- $0.77$2.75$2.04
62.25%
Downside
52 Weeks Volatility :72.0%
Upside
25.82%
Returns
| Period | Context Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -8.11% | 0.0% |
6 Months | 50.0% | 0.0% |
1 Year | 85.45% | 0.0% |
3 Years | -66.94% | -23.0% |
Highlights
Market Capitalization | 150.7M |
Book Value | $1.35 |
Earnings Per Share (EPS) | -0.96 |
Wall Street Target Price | 7.63 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.19% |
Return On Equity TTM | -29.68% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -20.0M |
Diluted Eps TTM | -0.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.34 |
EPS Estimate Next Year | -0.29 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.05 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 274.02%
Technicals Summary
Sell
Neutral
Buy
Context Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Context Therapeutics Inc | -1.92% | 50.0% | 85.45% | -66.94% | -60.0% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Context Therapeutics Inc | NA | NA | NA | -0.34 | -0.3 | -0.19 | NA | 1.35 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Context Therapeutics Inc | Buy | $150.7M | -60.0% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Context Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 2.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 111.7%
Institutional Holdings
Avidity Partners Management LP
9.89%Nextech Invest AG
9.89%Deep Track Capital, LP
9.89%Great Point Partners LLC
9.89%Blue Owl Capital Holdings LP
6.88%Vanguard Group Inc
6.00%
Company Information
context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.
Organization | Context Therapeutics Inc |
Employees | 5 |
CEO | Mr. Martin A. Lehr |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.04
+0.0%
Invesco Bulletshares 2025 Hi
$2.04
+0.0%
Schwab International Dividend Equity Etf
$2.04
+0.0%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.04
+0.0%
Lightpath Technologies Inc
$2.04
+0.0%
Vaneck Vectors Global Alternative Energy Etf
$2.04
+0.0%
First Trust Flexible Municipal High Income Etf
$2.04
+0.0%
Drx Dly Reg Bank Bull 3x
$2.04
+0.0%
Graniteshares 2x Long Pltr Daily Etf
$2.04
+0.0%